Noticeboard

Kia ora koutou 

I am very pleased to share this news about access to GLP1a dulaglutide.

From 1 July 2025, Pharmac is removing the 'no new patient restriction' on the GLP1a dulaglutide (branded as Trulicity).  This means people with type 2 diabetes, who meet the eligibility criteria, will be able to start on treatment with this medicine.

Learn more about the decision to enable new people to start treatment with dulaglutide for type 2 diabetes.

More information about the ongoing supply issue  is available on the Pharmac website: Dulaglutide(Trulicity) and Liraglutide (Victoza): Supply issue

Please also visit the   NZSSD Type 2 diabetes guidance   for information on when/in which patients it is appropriate to prescribe a GLP1Ra, and prescribing and monitoring recommendations.  

This is great news for people living with type 2 diabetes and the health professionals caring for them.

Ngā mihi nui

Jo

Dr Jo McClintock(she/her)

Consultant Clinical Psychologist |Kaimātai Hauora Hinengaro

President - New Zealand Society for the Study of Diabetes

president@nzssd.org.nz